Northland Capmk Has Positive Outlook of TLSI FY2026 Earnings

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) – Investment analysts at Northland Capmk upped their FY2026 earnings per share (EPS) estimates for shares of TriSalus Life Sciences in a report released on Tuesday, November 26th. Northland Capmk analyst C. Byrnes now forecasts that the company will post earnings of ($0.60) per share for the year, up from their prior forecast of ($0.75). Northland Capmk has a “Strong-Buy” rating on the stock. The consensus estimate for TriSalus Life Sciences’ current full-year earnings is ($1.55) per share.

A number of other equities research analysts have also weighed in on the company. Roth Capital raised TriSalus Life Sciences to a “strong-buy” rating in a research report on Monday, November 11th. Northland Securities assumed coverage on TriSalus Life Sciences in a report on Friday, October 25th. They issued an “outperform” rating and a $12.50 price target on the stock. Oppenheimer assumed coverage on TriSalus Life Sciences in a report on Monday, September 16th. They issued an “outperform” rating and a $10.00 price target on the stock. Canaccord Genuity Group cut their price target on TriSalus Life Sciences from $12.00 to $11.00 and set a “buy” rating on the stock in a report on Friday, November 15th. Finally, Roth Mkm assumed coverage on TriSalus Life Sciences in a report on Monday, November 11th. They issued a “buy” rating and a $11.00 price target on the stock. Six equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, TriSalus Life Sciences currently has a consensus rating of “Buy” and a consensus price target of $12.08.

TriSalus Life Sciences Stock Down 1.6 %

Shares of NASDAQ TLSI opened at $4.25 on Thursday. The business has a fifty day simple moving average of $4.23 and a two-hundred day simple moving average of $5.48. The firm has a market cap of $129.58 million, a PE ratio of -1.71 and a beta of 0.49. TriSalus Life Sciences has a twelve month low of $3.61 and a twelve month high of $10.42.

Insider Buying and Selling

In other TriSalus Life Sciences news, CEO Mary T. Szela bought 7,520 shares of the company’s stock in a transaction that occurred on Thursday, September 12th. The shares were purchased at an average cost of $5.20 per share, for a total transaction of $39,104.00. Following the purchase, the chief executive officer now directly owns 377,382 shares in the company, valued at $1,962,386.40. This represents a 2.03 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders have acquired a total of 19,560 shares of company stock worth $95,190 in the last ninety days. 32.80% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Highbridge Capital Management LLC purchased a new position in TriSalus Life Sciences during the 2nd quarter worth $1,184,000. Wolverine Asset Management LLC purchased a new stake in TriSalus Life Sciences during the 2nd quarter valued at about $240,000. Duquesne Family Office LLC grew its stake in TriSalus Life Sciences by 35.1% during the 2nd quarter. Duquesne Family Office LLC now owns 426,921 shares of the company’s stock valued at $2,357,000 after purchasing an additional 110,966 shares during the last quarter. Geode Capital Management LLC grew its stake in TriSalus Life Sciences by 45.4% during the 3rd quarter. Geode Capital Management LLC now owns 200,427 shares of the company’s stock valued at $924,000 after purchasing an additional 62,542 shares during the last quarter. Finally, Virtu Financial LLC purchased a new stake in TriSalus Life Sciences during the 3rd quarter valued at about $92,000. 2.58% of the stock is currently owned by hedge funds and other institutional investors.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.